Ainos Inc (AIMD)

Ainos, Inc.'s stock price has experienced fluctuations over the past six months. In August 2025, the stock traded up following FDA designations and compliance with Nasdaq's minimum bid requirements. In September 2025, the stock rose on positive data from an animal study trial of Veldona. In October 2025, Ainos announced a GICS reclassification and partnered with NEXCOM International Co., Ltd. In November 2025, Ainos announced a $2.1 million order for its AI Nose technology and explored a new healthcare market. In December 2025 - January 2026, Ainos entered into a distribution agreement with Trusval Technology Co. Ltd. and insider selling occurred. In February 2026, Ainos announced a strategic partnership with Mirle Automation Corporation, but the stock declined.

There is no explicit mention or indication of demand seasonality for Ainos, Inc.'s products and services.

Ainos, Inc. is a dual-platform company in the AI and biotechnology sectors, focusing on "smelltech" diagnostics and immune therapeutics. Its major products include the Smelltech Platform, which digitizes scent into a machine-readable data format, and VELDONA®, a low-dose oral interferon therapeutic targeting rare, autoimmune, and infectious diseases.

Ainos, Inc. has offices in Houston, Texas, and Zhubei City, Hsinchu County, Taiwan. Its AI Nose technology is being deployed in industrial environments, including semiconductor fabrication plants, and the company is pursuing robotics pilot programs in Japan.

Ainos, Inc.'s brand reputation appears mixed. The company has received a consensus "Sell" rating from analysts. It has actively pursued strategic partnerships, which are viewed as strategically positive. Market reactions to partnership news have been choppy. The company's revenue has remained minimal, and it has faced persistent net losses.

Ainos, Inc. has a mix of institutional and individual ownership, with 20 institutional owners holding 132,132 shares. Major institutional owners include Renaissance Technologies Llc and Vanguard Group Inc. Taiwan Carbon Nano Technology Corporation holds 14.18% of the company's shares. Ainos holds sole voting power over 3,536,073 shares, and insider ownership is reported at 76.25%.